The backtest results are unavailable for IVA's earnings beat event, providing no quantitative data or performance metrics. Without concrete results, it is impossible to analyze the stock's reaction or the magnitude of impact following the earnings beat. Consequently, investors lack evidence-based insights to guide decisions related to IVA after such earnings announcements.

The backtest results show that IVA experienced a 100% win rate with a 14.46% average return over 3 days and 6.12% over 10 days following an earnings miss, but returns turned slightly negative at -0.68% over 30 days. This indicates a strong short-term positive price reaction despite the earnings miss, peaking quickly within two days. Investors might consider short-term trading strategies to capitalize on immediate rebounds after earnings misses in IVA, while being cautious about holding positions longer term due to potential reversals.

backtest_data

The backtest results show that the Biotechnology Industry experienced a negative impact following earnings beats, with a maximum return of only 0.23% on the event day. This suggests that despite positive earnings surprises, the sector does not gain significant immediate upside and may even face mild adverse reactions. The analysis indicates that earnings beats in this industry do not translate into strong short-term gains, highlighting a cautious market sentiment.

Investors should be wary of expecting immediate positive returns from earnings beats in the Biotechnology sector and consider a more nuanced approach to trading these events.

The backtest results show that earnings misses in the Biotechnology Industry had no significant impact, with a maximum return of -0.04% observed on the event day. This negligible effect suggests that the market does not react strongly to earnings misses within this sector over the tested period.

The analysis indicates that investors may not need to adjust their positions based solely on earnings misses in Biotechnology stocks, as these events do not materially influence price movements.

Therefore, investment strategies should consider other factors beyond earnings misses when evaluating Biotechnology industry stocks.

Backtest IVA Earning Beats Expectations

Find all upcoming company earnings reports scheduled for feb 16 2026. Get details on which companies are reporting and their expected results.

Calendar